UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa (HS).

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, today announced the successful closing of its upsized ...

Vir Biotechnology, Inc. ( NASDAQ: VIR) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT ...

编者按：近年来，寡核苷酸类药物凭借其直接调控基因表达的独特机制，在中枢神经系统（CNS）疾病治疗领域展现出巨大潜力，受到业内广泛关注。迄今为止，美国FDA已批准多款寡核苷酸药物用于CNS疾病的治疗，如脊髓性肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS ...

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)Planning ...

High responses maintained over four years in nearly half of patients: 48.9% of Week 16 PASI 0 responders sustained complete ski ...